Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Immune Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 14
Partnerships 14
WuXi Biologics and Immune Pharma Enter into Co-Development Agreement 14
Immune Pharma Enters into Agreement with STC Biologics 15
Immune Pharma Plans to Partner with Hebrew University of Jerusalem 16
Immune Pharma Enters Into Co-Development Agreement With Yeda Research 17
Licensing Agreements 18
Immune Pharmaceuticals Enters into Licensing Agreement with Pint Pharma 18
SATT Sud Est Enters into Licensing Agreement with Immune Pharma 19
Maxim Pharma Enters into Licensing Agreement with Immune Pharma 20
Novel Pain Therapeutics Amends Option for Licensing Agreement with Immune Pharma 21
Immune Pharma Enters into Licensing Agreement with BioNanoSim 22
Immune Pharma Enters into Licensing Agreement with Yissum 23
Immune Pharma to Enter into Licensing Agreement with Yissum Research Development 25
Lonza Sales Enters into Licensing Agreement with Immune Pharma for Bertilimumab 26
Equity Offering 27
Immune Pharma Raises USD18 Million in Public Offering of Units 27
Immune Pharma Plans to Raise up to USD2.5 Million in Public Offering of Shares 29
Immune Pharma to Spin-off its Cytovia 30
Immune Pharma Plans to Raise up to USD3 Million in Public Offering of Shares 31
Immune Pharma Raises USD2 Million in Share Purchase Plan 32
Maxim Pharma to Raise upto USD20 Million in Private Placement of Shares 33
Immune Pharma Completes Spin Off of Pain and Neurology Business 34
Immune Pharma Raises USD1 Million in Private Placement of Shares 35
Immune Pharma Raises USD0.8 Million in Private Placement of Shares 36
Immune Pharma Raises USD1 Million in Private Placement of Shares 37
Immune Pharmaceuticals Raises USD9 Million in Private Placement of Series D Redeemable Convertible Preferred Stock 38
Immune Pharma Completes Underwriters Exercise of Partial Over-Allotment Option of Public Offering of Units for USD9.7 Million 40
Immune Pharma Raises USD1 Million in Private Placement of Units 41
Immune Pharma Raises USD11.7 Million in Private Placement of Units and Warrants 42
Debt Offering 43
Immune Pharma Raises USD1.5 Million in First Tanche of Private Placement of Debentures 43
Immune Pharma Raises USD0.5 Million in Private Placment of 6% Notes Due 2018 44
Immune Pharma Raises USD1 Million in Private Placement of Convertible Notes 45
Acquisition 46
Immune Pharma Completes Acquisition Of EpiCept In Reverse Takeover Transaction 46
Immune Pharmaceuticals Inc – Key Competitors 48
Immune Pharmaceuticals Inc – Key Employees 49
Immune Pharmaceuticals Inc – Locations And Subsidiaries 50
Head Office 50
Other Locations & Subsidiaries 50
Recent Developments 51
Strategy And Business Planning 51
Jul 19, 2017: Immune Pharmaceuticals Provides Update on Plan to Implement a Spin-off of Cytovia into a Separate Publicly Traded Oncology Company 51
Financial Announcements 52
Apr 02, 2018: Immune Pharmaceuticals Announces 2017 Financial Results 52
Nov 15, 2017: Immune Pharmaceuticals Announces Third Quarter 2017 Financial Results and Provides a Corporate Update 54
Aug 28, 2017: Immune Pharmaceuticals Provides Business Update and Summary of Recent Financial Highlights 56
Corporate Communications 57
Nov 27, 2017: Immune Provides Update Regarding NASDAQ US Listing and Departure of Officer 57
Aug 29, 2017: Immune Pharmaceuticals Receives NASDAQ Letter 58
Aug 14, 2017: Immune Pharmaceuticals Appoints Tony Fiorino, MD, PhD as Chief Medical Officer and Chief Operating Officer 59
Jun 19, 2017: Immune Receives NASDAQ Compliance Letter 60
May 26, 2017: Immune Receives Nasdaq Letters 61
Apr 24, 2017: Immune Receives Nasdaq Letter 62
Mar 13, 2017: Immune Pharmaceuticals Granted Additional Time to Comply with Nasdaq Listing Requirement 63
Jan 27, 2017: Immune Pharmaceuticals Appoints New Chairman of the Board of Directors 64
Government and Public Interest 65
Apr 24, 2017: Immune Pharmaceuticals Announces Corporate Restructuring 65
Other Significant Developments 66
Feb 20, 2018: Immune Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders and Provides Business Update 66
Aug 04, 2017: Immune Pharmaceuticals Issues Letter to Shareholders 69
Appendix 72
Methodology 72
About GlobalData 72
Contact Us 72
Disclaimer 72
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Immune Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 10
Immune Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
WuXi Biologics and Immune Pharma Enter into Co-Development Agreement 14
Immune Pharma Enters into Agreement with STC Biologics 15
Immune Pharma Plans to Partner with Hebrew University of Jerusalem 16
Immune Pharma Enters Into Co-Development Agreement With Yeda Research 17
Immune Pharmaceuticals Enters into Licensing Agreement with Pint Pharma 18
SATT Sud Est Enters into Licensing Agreement with Immune Pharma 19
Maxim Pharma Enters into Licensing Agreement with Immune Pharma 20
Novel Pain Therapeutics Amends Option for Licensing Agreement with Immune Pharma 21
Immune Pharma Enters into Licensing Agreement with BioNanoSim 22
Immune Pharma Enters into Licensing Agreement with Yissum 23
Immune Pharma to Enter into Licensing Agreement with Yissum Research Development 25
Lonza Sales Enters into Licensing Agreement with Immune Pharma for Bertilimumab 26
Immune Pharma Raises USD18 Million in Public Offering of Units 27
Immune Pharma Plans to Raise up to USD2.5 Million in Public Offering of Shares 29
Immune Pharma to Spin-off its Cytovia 30
Immune Pharma Plans to Raise up to USD3 Million in Public Offering of Shares 31
Immune Pharma Raises USD2 Million in Share Purchase Plan 32
Maxim Pharma to Raise upto USD20 Million in Private Placement of Shares 33
Immune Pharma Completes Spin Off of Pain and Neurology Business 34
Immune Pharma Raises USD1 Million in Private Placement of Shares 35
Immune Pharma Raises USD0.8 Million in Private Placement of Shares 36
Immune Pharma Raises USD1 Million in Private Placement of Shares 37
Immune Pharmaceuticals Raises USD9 Million in Private Placement of Series D Redeemable Convertible Preferred Stock 38
Immune Pharma Completes Underwriters Exercise of Partial Over-Allotment Option of Public Offering of Units for USD9.7 Million 40
Immune Pharma Raises USD1 Million in Private Placement of Units 41
Immune Pharma Raises USD11.7 Million in Private Placement of Units and Warrants 42
Immune Pharma Raises USD1.5 Million in First Tanche of Private Placement of Debentures 43
Immune Pharma Raises USD0.5 Million in Private Placment of 6% Notes Due 2018 44
Immune Pharma Raises USD1 Million in Private Placement of Convertible Notes 45
Immune Pharma Completes Acquisition Of EpiCept In Reverse Takeover Transaction 46
Immune Pharmaceuticals Inc, Key Competitors 48
Immune Pharmaceuticals Inc, Key Employees 49
Immune Pharmaceuticals Inc, Other Locations 50
Immune Pharmaceuticals Inc, Subsidiaries 50
List of Figures
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Immune Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11